BIOCYTOGEN PHARMA. H YC1 Working Capital to Net Assets Ratio
BIOCYTOGEN PHARMA. H YC1 working capital to net assets ratio. BIOCYTOGEN PHARMA. H YC1 (I54) has a Working Capital to Net Assets ratio of 55.9% as of December 2025. Working capital of €1.22 Billion (current assets of €2.15 Billion minus current liabilities of €930.31 Million) is measured against net assets of €2.18 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check BIOCYTOGEN PHARMA. H YC1 tangible book value ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of BIOCYTOGEN PHARMA. H YC1 (2021–2025)
Working capital to net assets ratio of BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025. This chart shows how BIOCYTOGEN PHARMA. H YC1's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 55.9%, reflecting working capital of €1.22 Billion against net assets of €2.18 Billion EUR. See operational self-sufficiency of BIOCYTOGEN PHARMA. H YC1 to measure how many days the company can operate on defensive assets alone.
BIOCYTOGEN PHARMA. H YC1 Working Capital to Net Assets Ratio by Year (2021–2025)
BIOCYTOGEN PHARMA. H YC1 working capital to net assets ratio by year from 2021 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see BIOCYTOGEN PHARMA. H YC1 total assets.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 55.9% | €1.22 Billion | €2.18 Billion | €2.15 Billion | €930.31 Million | ▲ +22.3 pp |
| 2024 | 33.6% | €281.62 Million | €838.60 Million | €816.53 Million | €534.91 Million | ▲ +15.2 pp |
| 2023 | 18.4% | €145.43 Million | €790.44 Million | €723.05 Million | €577.62 Million | ▼ -8.8 pp |
| 2022 | 27.2% | €313.25 Million | €1.15 Billion | €919.30 Million | €606.05 Million | ▼ -6.9 pp |
| 2021 | 34.2% | €427.68 Million | €1.25 Billion | €874.24 Million | €446.56 Million | — |